Stockholders' Equity Attributable to Parent in USD of Ambrx Biopharma Cayman, Inc. from Q4 2018 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Stockholders' Equity Attributable to Parent history and change rate from Q4 2018 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Stockholders' Equity Attributable to Parent for the quarter ending 30 Jun 2023 was $250M, a 76.5% increase year-over-year.
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2023 $250M +$108M +76.5% 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $183M +$13.6M +8.06% 31 Mar 2023 10-Q 09 Aug 2023
Q4 2022 $118M -$72.1M -38% 31 Dec 2022 10-Q 09 Aug 2023
Q2 2022 $142M -$50.9M -26.4% 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 $169M 31 Mar 2022 10-Q 09 Aug 2023
Q4 2021 $190M +$329M 31 Dec 2021 10-Q 09 Aug 2023
Q2 2021 $193M 30 Jun 2021 6-K 29 Aug 2022
Q4 2020 -$139M -$173M -517% 31 Dec 2020 10-K 30 Mar 2023
Q4 2019 $33.4M -$18.3M -35.3% 31 Dec 2019 20-F 26 Apr 2022
Q4 2018 $51.7M 31 Dec 2018 20-F 26 Apr 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.